Prosight discloses 5.8% ownership stake in OnKure Therapeutics

Prosight Management, LP and its affiliated investment entities have reported a collective ownership stake of roughly 5.8 percent in OnKure Therapeutics, Inc., a biotechnology company focused on oncology drug development. The disclosure covers shares of Class A common stock and was submitted in late November, triggered by share levels exceeding regulatory ownership thresholds.

The stake totals more than 745,000 shares, a figure calculated against the 12.8 million outstanding shares referenced in a recent prospectus. While sizable, the ownership remains non-controlling and is described as passive, with the group stating that the holdings were not acquired for the purpose of influencing management direction or corporate control.

Distribution of ownership across affiliated entities

Three core investment vehicles are listed as direct holders of the securities: Prosight Fund, LP; Prosight Plus Fund, LP; and multiple separately managed accounts operated under Prosight Management. Each is based in Delaware and collectively forms part of a coordinated shareholder group. Prosight Partners, LLC serves as the general partner to the management entity, while W. Lawrence Hawkins signs as the sole manager exercising oversight authority.

Prosight Fund, LP reports ownership of more than 35,000 shares, representing about 0.3 percent of the share class. Prosight Plus Fund, LP holds more than 163,000 shares, equivalent to approximately 1.3 percent. The remaining balance brings the aggregated total above the five-percent reporting threshold, placing the Prosight entities among the larger institutional holders of OnKure stock.

The group submitted under Rule 13d-1(c), indicating the position was not formed with activist intention. None of the entities identify as broker-dealers, banks, registered investment companies, or other special classifications, instead falling within categories associated with investment advisory and private fund management. The signed certification affirms that the shares were acquired solely for investment purposes and not to influence board composition or strategic direction.

OnKure Therapeutics continues to develop targeted cancer treatments from its headquarters in Boulder, Colorado, drawing institutional interest as its programs progress. Whether the Prosight group expands or rebalances its position over time may provide insight into long-term expectations for the company’s growth and clinical milestones.